Ultrafast Gene Fusion Assessment for Nonsquamous NSCLC

Abstract excerpt

Introduction Gene fusion testing of ALK , ROS1 , RET , NTRK , and MET exon 14 skipping mutations is guideline recommended in nonsquamous NSCLC (NS-NSCLC). Nevertheless, assessment is often hindered by the limited availability of tissue and prolonged next-generation sequencing (NGS) testing, which can protract the initiation of a targeted therapy. Therefore, the development of faster gene fusion assessment is...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Genomics and Diagnostics
• Share to Hepatocellular Carcinoma Treatment and Prognosis
• Share to Lung Cancer Treatments and Mutations